Introduction:Ebotec completed the round D financing of 1.2 billion yuan; Chengdu Geling completed a round A financing of 100 million yuan; Kang'enbei transferred 42% equity of Zhenshiming with 1.68 billion yuan
[Investment and Financing News DecembereightDay]Ebotec focuses on the construction of antibody platform and protein platform, and continuously introduces advanced antibody and protein technology to optimize the two platforms. The antibody platform includes rabbit polyclonal antibody platform, mouse monoclonal antibody platform and the newly introduced rabbit monoclonal antibody platform. Recently completed the D round of 1.2 billion yuanfinancing。
It is a familyinnovateDrug R&D and industrialization service providers,companyThe R&D pipeline covers the R&D of innovative drugs such as tumors (solid tumors and hematomas), autoimmune diseases, and cytokine storms caused by novel coronavirus pneumonia. Recently, the financing scale reached 106.5 million yuan in round A financing.
Zhenshiming Pharmaceutical Co., Ltd. is a manufacturer of Chinese and western medicine preparations. It has more than 40 varieties of eye drops, 6 products that have entered the national basic drug catalog, and 25 national medical insurance products. The total amount of equity financing completed a few days ago was 1.68 billion yuan.